Qbrelis (Lisinopril) Patent Expiration, LOE Window & CMS Spending

Qbrelis (Lisinopril) by Azurity: FDA Orange Book LOE 2035-11-06, 13 AB generics, $8.3M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAzurity
FDA Application & PathwayN208401 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2035-11-06
Orange Book Patents (*PED Extensions)12 patents (0 *PED)
Active AB-Rated Generic Competitors13
2024 CMS Total Public Spend$8.3M
2024 Medicare Part D Spend$2.2M
2024 Medicaid Spend$6.1M
Reported Wholesale Price Change (CA SB 17)3 WAC filings (max 26.4% 2-yr change)